CA2256721A1 - A nasal spray containing an intranasal steroid and an antihistamine - Google Patents

A nasal spray containing an intranasal steroid and an antihistamine Download PDF

Info

Publication number: CA2256721A1
Authority: CA; Canada
Prior art keywords: safe; mixtures; effective amount; present; acceptable salts
Prior art date: 1996-06-04
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA002256721A

Other languages

English (en)

French (fr)

Inventor

Patricia Elaine Koochaki

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Procter and Gamble Co

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-06-04

Filing date

1997-06-03

Publication date

1997-12-11

1997-06-03 Application filed by Individual filed Critical Individual

1997-12-11 Publication of CA2256721A1 publication Critical patent/CA2256721A1/en

Status Abandoned legal-status Critical Current

Links

GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 title claims abstract description 6
239000000739 antihistaminic agent Substances 0.000 title claims abstract description 6
230000001387 anti-histamine Effects 0.000 title claims abstract description 5
239000007922 nasal spray Substances 0.000 title description 4
229940097496 nasal spray Drugs 0.000 title description 4
150000003431 steroids Chemical class 0.000 title description 3
239000000203 mixture Substances 0.000 claims abstract description 66
-1 memetasone Chemical compound 0.000 claims abstract description 24
150000003839 salts Chemical class 0.000 claims abstract description 21
239000003862 glucocorticoid Substances 0.000 claims abstract description 16
201000010105 allergic rhinitis Diseases 0.000 claims abstract description 12
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 9
YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 claims abstract description 8
238000000034 method Methods 0.000 claims abstract description 8
208000035285 Allergic Seasonal Rhinitis Diseases 0.000 claims abstract description 7
206010039094 Rhinitis perennial Diseases 0.000 claims abstract description 7
208000036284 Rhinitis seasonal Diseases 0.000 claims abstract description 7
208000022719 perennial allergic rhinitis Diseases 0.000 claims abstract description 7
208000017022 seasonal allergic rhinitis Diseases 0.000 claims abstract description 7
ZZHLYYDVIOPZBE-UHFFFAOYSA-N Trimeprazine Chemical compound C1=CC=C2N(CC(CN(C)C)C)C3=CC=CC=C3SC2=C1 ZZHLYYDVIOPZBE-UHFFFAOYSA-N 0.000 claims abstract description 6
VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 claims abstract description 5
229960003792 acrivastine Drugs 0.000 claims abstract description 5
PWACSDKDOHSSQD-IUTFFREVSA-N acrivastine Chemical compound C1=CC(C)=CC=C1C(\C=1N=C(\C=C\C(O)=O)C=CC=1)=C/CN1CCCC1 PWACSDKDOHSSQD-IUTFFREVSA-N 0.000 claims abstract description 5
229940092705 beclomethasone Drugs 0.000 claims abstract description 5
NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 claims abstract description 5
229960004436 budesonide Drugs 0.000 claims abstract description 5
229960001140 cyproheptadine Drugs 0.000 claims abstract description 5
JJCFRYNCJDLXIK-UHFFFAOYSA-N cyproheptadine Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2C=CC2=CC=CC=C21 JJCFRYNCJDLXIK-UHFFFAOYSA-N 0.000 claims abstract description 5
229960005178 doxylamine Drugs 0.000 claims abstract description 5
HCFDWZZGGLSKEP-UHFFFAOYSA-N doxylamine Chemical compound C=1C=CC=NC=1C(C)(OCCN(C)C)C1=CC=CC=C1 HCFDWZZGGLSKEP-UHFFFAOYSA-N 0.000 claims abstract description 5
229960000676 flunisolide Drugs 0.000 claims abstract description 5
229960000930 hydroxyzine Drugs 0.000 claims abstract description 5
ZQDWXGKKHFNSQK-UHFFFAOYSA-N hydroxyzine Chemical compound C1CN(CCOCCO)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZQDWXGKKHFNSQK-UHFFFAOYSA-N 0.000 claims abstract description 5
MIXMJCQRHVAJIO-TZHJZOAOSA-N qk4dys664x Chemical compound O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O MIXMJCQRHVAJIO-TZHJZOAOSA-N 0.000 claims abstract description 5
DPPDPATYPQFYDL-UHFFFAOYSA-N 2-[2-(dimethylamino)ethyl]-4-methyl-2,3-dihydropyrido[3,2-f][1,4]oxazepine-5-thione Chemical compound O1C(CCN(C)C)CN(C)C(=S)C2=CC=CN=C21 DPPDPATYPQFYDL-UHFFFAOYSA-N 0.000 claims abstract description 4
OCJYIGYOJCODJL-UHFFFAOYSA-N Meclizine Chemical compound CC1=CC=CC(CN2CCN(CC2)C(C=2C=CC=CC=2)C=2C=CC(Cl)=CC=2)=C1 OCJYIGYOJCODJL-UHFFFAOYSA-N 0.000 claims abstract description 4
ZDIGNSYAACHWNL-UHFFFAOYSA-N brompheniramine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Br)C=C1 ZDIGNSYAACHWNL-UHFFFAOYSA-N 0.000 claims abstract description 4
229960000725 brompheniramine Drugs 0.000 claims abstract description 4
229960002504 capsaicin Drugs 0.000 claims abstract description 4
235000017663 capsaicin Nutrition 0.000 claims abstract description 4
229960000428 carbinoxamine Drugs 0.000 claims abstract description 4
OJFSXZCBGQGRNV-UHFFFAOYSA-N carbinoxamine Chemical compound C=1C=CC=NC=1C(OCCN(C)C)C1=CC=C(Cl)C=C1 OJFSXZCBGQGRNV-UHFFFAOYSA-N 0.000 claims abstract description 4
229960002714 fluticasone Drugs 0.000 claims abstract description 4
MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 claims abstract description 4
229960001474 meclozine Drugs 0.000 claims abstract description 4
229950003786 rocastine Drugs 0.000 claims abstract description 4
PWWVAXIEGOYWEE-UHFFFAOYSA-N Isophenergan Chemical compound C1=CC=C2N(CC(C)N(C)C)C3=CC=CC=C3SC2=C1 PWWVAXIEGOYWEE-UHFFFAOYSA-N 0.000 claims abstract description 3
229960003790 alimemazine Drugs 0.000 claims abstract description 3
SOYKEARSMXGVTM-UHFFFAOYSA-N chlorphenamine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 SOYKEARSMXGVTM-UHFFFAOYSA-N 0.000 claims abstract description 3
229960003291 chlorphenamine Drugs 0.000 claims abstract description 3
229960002881 clemastine Drugs 0.000 claims abstract description 3
YNNUSGIPVFPVBX-NHCUHLMSSA-N clemastine Chemical compound CN1CCC[C@@H]1CCO[C@@](C)(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 YNNUSGIPVFPVBX-NHCUHLMSSA-N 0.000 claims abstract description 3
229960000582 mepyramine Drugs 0.000 claims abstract description 3
YECBIJXISLIIDS-UHFFFAOYSA-N mepyramine Chemical compound C1=CC(OC)=CC=C1CN(CCN(C)C)C1=CC=CC=N1 YECBIJXISLIIDS-UHFFFAOYSA-N 0.000 claims abstract description 3
229960003910 promethazine Drugs 0.000 claims abstract description 3
ISFHAYSTHMVOJR-UHFFFAOYSA-N Phenindamine Chemical compound C1N(C)CCC(C2=CC=CC=C22)=C1C2C1=CC=CC=C1 ISFHAYSTHMVOJR-UHFFFAOYSA-N 0.000 claims abstract 2
UFLGIAIHIAPJJC-UHFFFAOYSA-N Tripelennamine Chemical compound C=1C=CC=NC=1N(CCN(C)C)CC1=CC=CC=C1 UFLGIAIHIAPJJC-UHFFFAOYSA-N 0.000 claims abstract 2
229960000383 azatadine Drugs 0.000 claims abstract 2
SEBMTIQKRHYNIT-UHFFFAOYSA-N azatadine Chemical compound C1CN(C)CCC1=C1C2=NC=CC=C2CCC2=CC=CC=C21 SEBMTIQKRHYNIT-UHFFFAOYSA-N 0.000 claims abstract 2
229960004056 methdilazine Drugs 0.000 claims abstract 2
HTMIBDQKFHUPSX-UHFFFAOYSA-N methdilazine Chemical compound C1N(C)CCC1CN1C2=CC=CC=C2SC2=CC=CC=C21 HTMIBDQKFHUPSX-UHFFFAOYSA-N 0.000 claims abstract 2
229960003534 phenindamine Drugs 0.000 claims abstract 2
229960003223 tripelennamine Drugs 0.000 claims abstract 2
WYWIFABBXFUGLM-UHFFFAOYSA-N oxymetazoline Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C)=C1CC1=NCCN1 WYWIFABBXFUGLM-UHFFFAOYSA-N 0.000 claims description 8
BYJAVTDNIXVSPW-UHFFFAOYSA-N tetryzoline Chemical compound N1CCN=C1C1C2=CC=CC=C2CCC1 BYJAVTDNIXVSPW-UHFFFAOYSA-N 0.000 claims description 6
230000000631 nonopiate Effects 0.000 claims description 4
229960001528 oxymetazoline Drugs 0.000 claims description 4
229960001128 triprolidine Drugs 0.000 claims description 4
CBEQULMOCCWAQT-WOJGMQOQSA-N triprolidine Chemical compound C1=CC(C)=CC=C1C(\C=1N=CC=CC=1)=C/CN1CCCC1 CBEQULMOCCWAQT-WOJGMQOQSA-N 0.000 claims description 4
ZCVMWBYGMWKGHF-UHFFFAOYSA-N Ketotifene Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2CC(=O)C2=C1C=CS2 ZCVMWBYGMWKGHF-UHFFFAOYSA-N 0.000 claims description 3
229960004958 ketotifen Drugs 0.000 claims description 3
229960001802 phenylephrine Drugs 0.000 claims description 3
SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 claims description 3
229960000337 tetryzoline Drugs 0.000 claims description 3
JTOUASWUIMAMAD-UHFFFAOYSA-N 7-[2-hydroxy-3-[4-(3-phenylsulfanylpropyl)piperazin-1-yl]propyl]-1,3-dimethylpurine-2,6-dione Chemical compound C1=2C(=O)N(C)C(=O)N(C)C=2N=CN1CC(O)CN(CC1)CCN1CCCSC1=CC=CC=C1 JTOUASWUIMAMAD-UHFFFAOYSA-N 0.000 claims description 2
ZKLPARSLTMPFCP-UHFFFAOYSA-N Cetirizine Chemical compound C1CN(CCOCC(=O)O)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZKLPARSLTMPFCP-UHFFFAOYSA-N 0.000 claims description 2
239000000150 Sympathomimetic Substances 0.000 claims description 2
150000001412 amines Chemical class 0.000 claims description 2
239000007864 aqueous solution Substances 0.000 claims description 2
229960001803 cetirizine Drugs 0.000 claims description 2
229960001971 ebastine Drugs 0.000 claims description 2
MJJALKDDGIKVBE-UHFFFAOYSA-N ebastine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(=O)CCCN1CCC(OC(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 MJJALKDDGIKVBE-UHFFFAOYSA-N 0.000 claims description 2
229950004607 tazifylline Drugs 0.000 claims description 2
QQJLHRRUATVHED-UHFFFAOYSA-N tramazoline Chemical compound N1CCN=C1NC1=CC=CC2=C1CCCC2 QQJLHRRUATVHED-UHFFFAOYSA-N 0.000 claims description 2
229960001262 tramazoline Drugs 0.000 claims description 2
CNIIGCLFLJGOGP-UHFFFAOYSA-N 2-(1-naphthalenylmethyl)-4,5-dihydro-1H-imidazole Chemical compound C=1C=CC2=CC=CC=C2C=1CC1=NCCN1 CNIIGCLFLJGOGP-UHFFFAOYSA-N 0.000 claims 2
MBUVEWMHONZEQD-UHFFFAOYSA-N Azeptin Chemical compound C1CN(C)CCCC1N1C(=O)C2=CC=CC=C2C(CC=2C=CC(Cl)=CC=2)=N1 MBUVEWMHONZEQD-UHFFFAOYSA-N 0.000 claims 1
239000000867 Lipoxygenase Inhibitor Substances 0.000 claims 1
229940122142 Lipoxygenase inhibitor Drugs 0.000 claims 1
HOKDBMAJZXIPGC-UHFFFAOYSA-N Mequitazine Chemical compound C12=CC=CC=C2SC2=CC=CC=C2N1CC1C(CC2)CCN2C1 HOKDBMAJZXIPGC-UHFFFAOYSA-N 0.000 claims 1
OGEAASSLWZDQBM-UHFFFAOYSA-N Temelastine Chemical compound C1=NC(C)=CC=C1CC(C(N1)=O)=CN=C1NCCCCC1=NC=C(Br)C=C1C OGEAASSLWZDQBM-UHFFFAOYSA-N 0.000 claims 1
230000000202 analgesic effect Effects 0.000 claims 1
239000005557 antagonist Substances 0.000 claims 1
GXDALQBWZGODGZ-UHFFFAOYSA-N astemizole Chemical compound C1=CC(OC)=CC=C1CCN1CCC(NC=2N(C3=CC=CC=C3N=2)CC=2C=CC(F)=CC=2)CC1 GXDALQBWZGODGZ-UHFFFAOYSA-N 0.000 claims 1
229960004574 azelastine Drugs 0.000 claims 1
DLNKOYKMWOXYQA-UHFFFAOYSA-N dl-pseudophenylpropanolamine Natural products CC(N)C(O)C1=CC=CC=C1 DLNKOYKMWOXYQA-UHFFFAOYSA-N 0.000 claims 1
229960001120 levocabastine Drugs 0.000 claims 1
ZCGOMHNNNFPNMX-KYTRFIICSA-N levocabastine Chemical compound C1([C@@]2(C(O)=O)CCN(C[C@H]2C)[C@@H]2CC[C@@](CC2)(C#N)C=2C=CC(F)=CC=2)=CC=CC=C1 ZCGOMHNNNFPNMX-KYTRFIICSA-N 0.000 claims 1
229960003088 loratadine Drugs 0.000 claims 1
JCCNYMKQOSZNPW-UHFFFAOYSA-N loratadine Chemical compound C1CN(C(=O)OCC)CCC1=C1C2=NC=CC=C2CCC2=CC(Cl)=CC=C21 JCCNYMKQOSZNPW-UHFFFAOYSA-N 0.000 claims 1
229960005042 mequitazine Drugs 0.000 claims 1
229960005016 naphazoline Drugs 0.000 claims 1
239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 1
229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 1
229960002698 oxatomide Drugs 0.000 claims 1
BAINIUMDFURPJM-UHFFFAOYSA-N oxatomide Chemical compound O=C1NC2=CC=CC=C2N1CCCN(CC1)CCN1C(C=1C=CC=CC=1)C1=CC=CC=C1 BAINIUMDFURPJM-UHFFFAOYSA-N 0.000 claims 1
229960000395 phenylpropanolamine Drugs 0.000 claims 1
DLNKOYKMWOXYQA-APPZFPTMSA-N phenylpropanolamine Chemical compound C[C@@H](N)[C@H](O)C1=CC=CC=C1 DLNKOYKMWOXYQA-APPZFPTMSA-N 0.000 claims 1
229950010450 pseudophedrine Drugs 0.000 claims 1
229950003911 setastine Drugs 0.000 claims 1
VBSPHZOBAOWFCL-UHFFFAOYSA-N setastine Chemical compound C=1C=CC=CC=1C(C=1C=CC(Cl)=CC=1)(C)OCCN1CCCCCC1 VBSPHZOBAOWFCL-UHFFFAOYSA-N 0.000 claims 1
230000001975 sympathomimetic effect Effects 0.000 claims 1
229950005829 temelastine Drugs 0.000 claims 1
229960000351 terfenadine Drugs 0.000 claims 1
208000024891 symptom Diseases 0.000 abstract description 16
230000001932 seasonal effect Effects 0.000 abstract description 7
239000008187 granular material Substances 0.000 abstract description 3
239000000843 powder Substances 0.000 abstract description 3
229960000520 diphenhydramine Drugs 0.000 abstract description 2
ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 abstract description 2
239000003795 chemical substances by application Substances 0.000 description 19
239000004615 ingredient Substances 0.000 description 11
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
206010020751 Hypersensitivity Diseases 0.000 description 8
208000026935 allergic disease Diseases 0.000 description 8
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 6
239000003755 preservative agent Substances 0.000 description 6
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
206010039085 Rhinitis allergic Diseases 0.000 description 5
239000002552 dosage form Substances 0.000 description 5
230000000694 effects Effects 0.000 description 5
239000000243 solution Substances 0.000 description 5
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 4
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
230000007815 allergy Effects 0.000 description 4
239000001913 cellulose Substances 0.000 description 4
235000010980 cellulose Nutrition 0.000 description 4
229940079593 drug Drugs 0.000 description 4
239000003814 drug Substances 0.000 description 4
239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 4
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 4
229920000053 polysorbate 80 Polymers 0.000 description 4
229940068968 polysorbate 80 Drugs 0.000 description 4
239000011780 sodium chloride Substances 0.000 description 4
230000000699 topical effect Effects 0.000 description 4
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
150000001875 compounds Chemical class 0.000 description 3
239000003246 corticosteroid Substances 0.000 description 3
239000008121 dextrose Substances 0.000 description 3
WTEVQBCEXWBHNA-JXMROGBWSA-N geranial Chemical compound CC(C)=CCC\C(C)=C\C=O WTEVQBCEXWBHNA-JXMROGBWSA-N 0.000 description 3
210000003630 histaminocyte Anatomy 0.000 description 3
230000007794 irritation Effects 0.000 description 3
229940067107 phenylethyl alcohol Drugs 0.000 description 3
230000002335 preservative effect Effects 0.000 description 3
239000007921 spray Substances 0.000 description 3
BDDLHHRCDSJVKV-UHFFFAOYSA-N 7028-40-2 Chemical compound CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O BDDLHHRCDSJVKV-UHFFFAOYSA-N 0.000 description 2
241000167854 Bourreria succulenta Species 0.000 description 2
WTEVQBCEXWBHNA-UHFFFAOYSA-N Citral Natural products CC(C)=CCCC(C)=CC=O WTEVQBCEXWBHNA-UHFFFAOYSA-N 0.000 description 2
235000005979 Citrus limon Nutrition 0.000 description 2
244000131522 Citrus pyriformis Species 0.000 description 2
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
239000002202 Polyethylene glycol Substances 0.000 description 2
YEEZWCHGZNKEEK-UHFFFAOYSA-N Zafirlukast Chemical compound COC1=CC(C(=O)NS(=O)(=O)C=2C(=CC=CC=2)C)=CC=C1CC(C1=C2)=CN(C)C1=CC=C2NC(=O)OC1CCCC1 YEEZWCHGZNKEEK-UHFFFAOYSA-N 0.000 description 2
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
230000001154 acute effect Effects 0.000 description 2
150000001299 aldehydes Chemical class 0.000 description 2
230000000172 allergic effect Effects 0.000 description 2
229940035676 analgesics Drugs 0.000 description 2
239000000730 antalgic agent Substances 0.000 description 2
230000003266 anti-allergic effect Effects 0.000 description 2
239000000043 antiallergic agent Substances 0.000 description 2
125000003118 aryl group Chemical group 0.000 description 2
208000010668 atopic eczema Diseases 0.000 description 2
229960000686 benzalkonium chloride Drugs 0.000 description 2
CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 2
RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
239000001768 carboxy methyl cellulose Substances 0.000 description 2
239000000969 carrier Substances 0.000 description 2
229920002678 cellulose Polymers 0.000 description 2
229920006184 cellulose methylcellulose Polymers 0.000 description 2
235000019693 cherries Nutrition 0.000 description 2
OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
230000001684 chronic effect Effects 0.000 description 2
235000020971 citrus fruits Nutrition 0.000 description 2
229960000265 cromoglicic acid Drugs 0.000 description 2
KSMVZQYAVGTKIV-UHFFFAOYSA-N decanal Chemical compound CCCCCCCCCC=O KSMVZQYAVGTKIV-UHFFFAOYSA-N 0.000 description 2
239000000850 decongestant Substances 0.000 description 2
229940124581 decongestants Drugs 0.000 description 2
VLARUOGDXDTHEH-UHFFFAOYSA-L disodium cromoglycate Chemical compound [Na+].[Na+].O1C(C([O-])=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C([O-])=O)O2 VLARUOGDXDTHEH-UHFFFAOYSA-L 0.000 description 2
239000012153 distilled water Substances 0.000 description 2
150000002148 esters Chemical class 0.000 description 2
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
235000011187 glycerol Nutrition 0.000 description 2
229940065725 leukotriene receptor antagonists for obstructive airway diseases Drugs 0.000 description 2
239000003199 leukotriene receptor blocking agent Substances 0.000 description 2
210000004379 membrane Anatomy 0.000 description 2
239000012528 membrane Substances 0.000 description 2
239000002207 metabolite Substances 0.000 description 2
MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 2
229920000609 methyl cellulose Polymers 0.000 description 2
239000001923 methylcellulose Substances 0.000 description 2
235000010981 methylcellulose Nutrition 0.000 description 2
150000004682 monohydrates Chemical class 0.000 description 2
231100000252 nontoxic Toxicity 0.000 description 2
230000003000 nontoxic effect Effects 0.000 description 2
229920001223 polyethylene glycol Polymers 0.000 description 2
229920000642 polymer Polymers 0.000 description 2
239000008213 purified water Substances 0.000 description 2
102000005962 receptors Human genes 0.000 description 2
108020003175 receptors Proteins 0.000 description 2
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
239000000600 sorbitol Substances 0.000 description 2
239000000725 suspension Substances 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
239000002562 thickening agent Substances 0.000 description 2
NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
JXYWFNAQESKDNC-BTJKTKAUSA-N (z)-4-hydroxy-4-oxobut-2-enoate;2-[(4-methoxyphenyl)methyl-pyridin-2-ylamino]ethyl-dimethylazanium Chemical compound OC(=O)\C=C/C(O)=O.C1=CC(OC)=CC=C1CN(CCN(C)C)C1=CC=CC=N1 JXYWFNAQESKDNC-BTJKTKAUSA-N 0.000 description 1
WEEGYLXZBRQIMU-UHFFFAOYSA-N 1,8-cineole Natural products C1CC2CCC1(C)OC2(C)C WEEGYLXZBRQIMU-UHFFFAOYSA-N 0.000 description 1
CBOBADCVMLMQRW-UHFFFAOYSA-N 2,6-dimethyloctanal Chemical compound CCC(C)CCCC(C)C=O CBOBADCVMLMQRW-UHFFFAOYSA-N 0.000 description 1
HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
WONYMNWUJVKVII-UHFFFAOYSA-N 3,5-diiodothyropropionic acid Chemical compound IC1=CC(CCC(=O)O)=CC(I)=C1OC1=CC=C(O)C=C1 WONYMNWUJVKVII-UHFFFAOYSA-N 0.000 description 1
VXEBMQZDPONDFB-UHFFFAOYSA-N 4-(2h-tetrazol-5-yl)-n-[4-(2h-tetrazol-5-yl)phenyl]benzamide Chemical compound C=1C=C(C2=NNN=N2)C=CC=1C(=O)NC(C=C1)=CC=C1C=1N=NNN=1 VXEBMQZDPONDFB-UHFFFAOYSA-N 0.000 description 1
BSYNRYMUTXBXSQ-FOQJRBATSA-N 59096-14-9 Chemical compound CC(=O)OC1=CC=CC=C1[14C](O)=O BSYNRYMUTXBXSQ-FOQJRBATSA-N 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
235000011437 Amygdalus communis Nutrition 0.000 description 1
244000144725 Amygdalus communis Species 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
244000025254 Cannabis sativa Species 0.000 description 1
241000207199 Citrus Species 0.000 description 1
235000008733 Citrus aurantifolia Nutrition 0.000 description 1
241001672694 Citrus reticulata Species 0.000 description 1
102000010918 Cysteinyl leukotriene receptors Human genes 0.000 description 1
108050001116 Cysteinyl leukotriene receptors Proteins 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 description 1
ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
WEEGYLXZBRQIMU-WAAGHKOSSA-N Eucalyptol Chemical compound C1C[C@H]2CC[C@]1(C)OC2(C)C WEEGYLXZBRQIMU-WAAGHKOSSA-N 0.000 description 1
206010051841 Exposure to allergen Diseases 0.000 description 1
239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
102000003820 Lipoxygenases Human genes 0.000 description 1
108090000128 Lipoxygenases Proteins 0.000 description 1
235000006679 Mentha X verticillata Nutrition 0.000 description 1
235000002899 Mentha suaveolens Nutrition 0.000 description 1
235000001636 Mentha x rotundifolia Nutrition 0.000 description 1
XADCESSVHJOZHK-UHFFFAOYSA-N Meperidine Chemical compound C=1C=CC=CC=1C1(C(=O)OCC)CCN(C)CC1 XADCESSVHJOZHK-UHFFFAOYSA-N 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
206010028735 Nasal congestion Diseases 0.000 description 1
206010052437 Nasal discomfort Diseases 0.000 description 1
241000282320 Panthera leo Species 0.000 description 1
229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
229920002701 Polyoxyl 40 Stearate Polymers 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
NBQKINXMPLXUET-UHFFFAOYSA-N Pranlukast Chemical compound C=1C=C(OCCCCC=2C=CC=CC=2)C=CC=1C(=O)NC1=CC=CC(C(C=2)=O)=C1OC=2C=1N=NNN=1 NBQKINXMPLXUET-UHFFFAOYSA-N 0.000 description 1
229920002125 Sokalan® Polymers 0.000 description 1
206010041349 Somnolence Diseases 0.000 description 1
235000011941 Tilia x europaea Nutrition 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
229940020697 accolate Drugs 0.000 description 1
229960004308 acetylcysteine Drugs 0.000 description 1
230000004913 activation Effects 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
230000002411 adverse Effects 0.000 description 1
239000013572 airborne allergen Substances 0.000 description 1
125000000217 alkyl group Chemical group 0.000 description 1
239000013566 allergen Substances 0.000 description 1
235000020224 almond Nutrition 0.000 description 1
229950002999 andolast Drugs 0.000 description 1
230000000845 anti-microbial effect Effects 0.000 description 1
229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 description 1
229940125715 antihistaminic agent Drugs 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
239000007900 aqueous suspension Substances 0.000 description 1
YNKMHABLMGIIFX-UHFFFAOYSA-N benzaldehyde;methane Chemical compound C.O=CC1=CC=CC=C1 YNKMHABLMGIIFX-UHFFFAOYSA-N 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
239000004327 boric acid Substances 0.000 description 1
239000006172 buffering agent Substances 0.000 description 1
RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 description 1
229960001736 buprenorphine Drugs 0.000 description 1
229960001948 caffeine Drugs 0.000 description 1
VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
229960003333 chlorhexidine gluconate Drugs 0.000 description 1
YZIYKJHYYHPJIB-UUPCJSQJSA-N chlorhexidine gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.C1=CC(Cl)=CC=C1NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NC1=CC=C(Cl)C=C1 YZIYKJHYYHPJIB-UUPCJSQJSA-N 0.000 description 1
229960004926 chlorobutanol Drugs 0.000 description 1
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol group Chemical group [C@@H]1(CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)[C@H](C)CCCC(C)C HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 1
239000000812 cholinergic antagonist Substances 0.000 description 1
229960005233 cineole Drugs 0.000 description 1
229940043350 citral Drugs 0.000 description 1
WTEVQBCEXWBHNA-YFHOEESVSA-N citral B Natural products CC(C)=CCC\C(C)=C/C=O WTEVQBCEXWBHNA-YFHOEESVSA-N 0.000 description 1
238000004040 coloring Methods 0.000 description 1
229960001334 corticosteroids Drugs 0.000 description 1
239000002178 crystalline material Substances 0.000 description 1
YRCPIXCRSAKRGM-UHFFFAOYSA-N cyclopentyl n-[1-[[4-(benzenesulfonylcarbamoyl)-2-methoxyphenyl]methyl]indazol-6-yl]carbamate Chemical compound COC1=CC(C(=O)NS(=O)(=O)C=2C=CC=CC=2)=CC=C1CN(C1=C2)N=CC1=CC=C2NC(=O)OC1CCCC1 YRCPIXCRSAKRGM-UHFFFAOYSA-N 0.000 description 1
KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
XLMALTXPSGQGBX-GCJKJVERSA-N dextropropoxyphene Chemical compound C([C@](OC(=O)CC)([C@H](C)CN(C)C)C=1C=CC=CC=1)C1=CC=CC=C1 XLMALTXPSGQGBX-GCJKJVERSA-N 0.000 description 1
229960004193 dextropropoxyphene Drugs 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
238000012377 drug delivery Methods 0.000 description 1
238000009510 drug design Methods 0.000 description 1
238000001035 drying Methods 0.000 description 1
235000013399 edible fruits Nutrition 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
229960005293 etodolac Drugs 0.000 description 1
XFBVBWWRPKNWHW-UHFFFAOYSA-N etodolac Chemical compound C1COC(CC)(CC(O)=O)C2=N[C]3C(CC)=CC=CC3=C21 XFBVBWWRPKNWHW-UHFFFAOYSA-N 0.000 description 1
239000003172 expectorant agent Substances 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
PJMPHNIQZUBGLI-UHFFFAOYSA-N fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 description 1
229960002428 fentanyl Drugs 0.000 description 1
239000012530 fluid Substances 0.000 description 1
MCPSMQGVSYDFLC-UHFFFAOYSA-N formaldehyde;2-octylphenol Chemical group O=C.CCCCCCCCC1=CC=CC=C1O MCPSMQGVSYDFLC-UHFFFAOYSA-N 0.000 description 1
238000009472 formulation Methods 0.000 description 1
239000003205 fragrance Substances 0.000 description 1
239000000499 gel Substances 0.000 description 1
235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
229960001680 ibuprofen Drugs 0.000 description 1
238000009169 immunotherapy Methods 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
238000011835 investigation Methods 0.000 description 1
239000002085 irritant Substances 0.000 description 1
231100000021 irritant Toxicity 0.000 description 1
230000007803 itching Effects 0.000 description 1
DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
229960000991 ketoprofen Drugs 0.000 description 1
229960004752 ketorolac Drugs 0.000 description 1
OZWKMVRBQXNZKK-UHFFFAOYSA-N ketorolac Chemical compound OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 OZWKMVRBQXNZKK-UHFFFAOYSA-N 0.000 description 1
239000004571 lime Substances 0.000 description 1
239000007788 liquid Substances 0.000 description 1
238000005259 measurement Methods 0.000 description 1
229940041616 menthol Drugs 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
239000002395 mineralocorticoid Substances 0.000 description 1
229960001664 mometasone Drugs 0.000 description 1
QLIIKPVHVRXHRI-CXSFZGCWSA-N mometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CCl)(O)[C@@]1(C)C[C@@H]2O QLIIKPVHVRXHRI-CXSFZGCWSA-N 0.000 description 1
230000000510 mucolytic effect Effects 0.000 description 1
229940066491 mucolytics Drugs 0.000 description 1
210000004877 mucosa Anatomy 0.000 description 1
210000004400 mucous membrane Anatomy 0.000 description 1
MYWUZJCMWCOHBA-UHFFFAOYSA-N n-methyl-1-phenylpropan-2-amine Chemical compound CNC(C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-UHFFFAOYSA-N 0.000 description 1
NETZHAKZCGBWSS-CEDHKZHLSA-N nalbuphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]1(O)CC[C@@H]3O)CN2CC1CCC1 NETZHAKZCGBWSS-CEDHKZHLSA-N 0.000 description 1
229960000805 nalbuphine Drugs 0.000 description 1
229960002009 naproxen Drugs 0.000 description 1
CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
229940100652 nasal gel Drugs 0.000 description 1
210000002850 nasal mucosa Anatomy 0.000 description 1
229940100656 nasal solution Drugs 0.000 description 1
GYHFUZHODSMOHU-UHFFFAOYSA-N nonanal Chemical compound CCCCCCCCC=O GYHFUZHODSMOHU-UHFFFAOYSA-N 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
NUJGJRNETVAIRJ-UHFFFAOYSA-N octanal Chemical compound CCCCCCCC=O NUJGJRNETVAIRJ-UHFFFAOYSA-N 0.000 description 1
229940066429 octoxynol Drugs 0.000 description 1
229920002113 octoxynol Polymers 0.000 description 1
229950004864 olamine Drugs 0.000 description 1
229940127240 opiate Drugs 0.000 description 1
239000000014 opioid analgesic Substances 0.000 description 1
229940005483 opioid analgesics Drugs 0.000 description 1
230000003204 osmotic effect Effects 0.000 description 1
OFPXSFXSNFPTHF-UHFFFAOYSA-N oxaprozin Chemical compound O1C(CCC(=O)O)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 OFPXSFXSNFPTHF-UHFFFAOYSA-N 0.000 description 1
210000005037 parasympathetic nerve Anatomy 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
229960000482 pethidine Drugs 0.000 description 1
CPJSUEIXXCENMM-UHFFFAOYSA-N phenacetin Chemical compound CCOC1=CC=C(NC(C)=O)C=C1 CPJSUEIXXCENMM-UHFFFAOYSA-N 0.000 description 1
150000003053 piperidines Chemical class 0.000 description 1
229940099429 polyoxyl 40 stearate Drugs 0.000 description 1
239000011591 potassium Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
JCRIVQIOJSSCQD-UHFFFAOYSA-N propylhexedrine Chemical compound CNC(C)CC1CCCCC1 JCRIVQIOJSSCQD-UHFFFAOYSA-N 0.000 description 1
229960000786 propylhexedrine Drugs 0.000 description 1
229960003908 pseudoephedrine Drugs 0.000 description 1
KWGRBVOPPLSCSI-WCBMZHEXSA-N pseudoephedrine Chemical compound CN[C@@H](C)[C@@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WCBMZHEXSA-N 0.000 description 1
229940044551 receptor antagonist Drugs 0.000 description 1
239000002464 receptor antagonist Substances 0.000 description 1
238000011160 research Methods 0.000 description 1
238000012552 review Methods 0.000 description 1
239000012266 salt solution Substances 0.000 description 1
230000028327 secretion Effects 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
HELHAJAZNSDZJO-OLXYHTOASA-L sodium L-tartrate Chemical compound [Na+].[Na+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O HELHAJAZNSDZJO-OLXYHTOASA-L 0.000 description 1
229910001415 sodium ion Inorganic materials 0.000 description 1
239000001488 sodium phosphate Substances 0.000 description 1
229910000162 sodium phosphate Inorganic materials 0.000 description 1
239000001433 sodium tartrate Substances 0.000 description 1
229960002167 sodium tartrate Drugs 0.000 description 1
235000011004 sodium tartrates Nutrition 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
229940127230 sympathomimetic drug Drugs 0.000 description 1
RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
229940033663 thimerosal Drugs 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
229960002117 triamcinolone acetonide Drugs 0.000 description 1
YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 description 1
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
229920001664 tyloxapol Polymers 0.000 description 1
229960004224 tyloxapol Drugs 0.000 description 1
MDYZKJNTKZIUSK-UHFFFAOYSA-N tyloxapol Chemical compound O=C.C1CO1.CC(C)(C)CC(C)(C)C1=CC=C(O)C=C1 MDYZKJNTKZIUSK-UHFFFAOYSA-N 0.000 description 1
230000000007 visual effect Effects 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1
229960004764 zafirlukast Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents

Landscapes

Health & Medical Sciences (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Immunology (AREA)
Bioinformatics & Cheminformatics (AREA)
Pulmonology (AREA)
Epidemiology (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

CA002256721A 1996-06-04 1997-06-03 A nasal spray containing an intranasal steroid and an antihistamine Abandoned CA2256721A1 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US65750696A	1996-06-04	1996-06-04
US08/657,506		1996-06-04
PCT/US1997/009518 WO1997046243A1 (en)	1996-06-04	1997-06-03	A nasal spray containing an intranasal steroid and an antihistamine

Publications (1)

Publication Number	Publication Date
CA2256721A1 true CA2256721A1 (en)	1997-12-11

Family

ID=24637461

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002256721A Abandoned CA2256721A1 (en)	1996-06-04	1997-06-03	A nasal spray containing an intranasal steroid and an antihistamine

Country Status (6)

Country	Link
EP (1)	EP0954318A1 (de)
JP (1)	JPH11511758A (de)
AU (1)	AU3153797A (de)
BR (1)	BR9709650A (de)
CA (1)	CA2256721A1 (de)
WO (1)	WO1997046243A1 (de)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5976573A (en) *	1996-07-03	1999-11-02	Rorer Pharmaceutical Products Inc.	Aqueous-based pharmaceutical composition
FR2756739B1 (fr) *	1996-12-05	2000-04-28	Astra Ab	Nouvelle formulation de budesonide
SK286103B6 (sk) *	1997-12-23	2008-03-05	Schering Corporation	Farmaceutický prostriedok na liečenie respiračných a kožných ochorení s obsahom aspoň jedného antagonistu leukotriénu a aspoň jedného antihistaminikaa jeho použitie
US6248308B1 (en)	1998-04-14	2001-06-19	Sepracor Inc.	Methods of using norastemizole in combination with leukotriene inhibitors to treat or prevent asthma
US6245785B1 (en)	1998-11-30	2001-06-12	Warner Lambert Company	Dissolution of triprolidine hydrochloride
EP1020233A1 (de)	1999-01-13	2000-07-19	The Procter & Gamble Company	Dosierungs- und Verteilungssystem
DE19924525A1 (de) *	1999-05-28	2000-11-30	Ruediger Scheunemann	Kombination eines modernen topischen Glukokortikosteroids mit abschwellenden Nasentropfen
IT1313567B1 (it) *	1999-07-27	2002-09-09	Zambon Spa	Uso della n-acetil-cisteina per la preparazione di composizionifarmaceutiche topiche per il trattamento di patologie allergiche delle
GB9918559D0 (en)	1999-08-07	1999-10-06	Glaxo Wellcome Kk	Novel pharmaceutical formulation
DE19947234A1 (de) *	1999-09-30	2001-04-05	Asta Medica Ag	Neue Kombination von Loteprednol und Antihistaminika
ES2284531T3 (es) *	1999-10-08	2007-11-16	Schering Corporation	Tratamiento nasal topico usando desloratadina y furoato de mometasona.
ATE466611T1 (de)	2000-04-03	2010-05-15	Battelle Memorial Institute	Ausgabevorrichtungen und flüssigformulierungen
US6759398B2 (en)	2000-08-05	2004-07-06	Smithkline Beecham Corporation	Anti-inflammatory androstane derivative
US6858593B2 (en)	2000-08-05	2005-02-22	Smithkline Beecham Corporation	Anti-inflammatory androstane derivative compositions
US6858596B2 (en)	2000-08-05	2005-02-22	Smithkline Beecham Corporation	Formulation containing anti-inflammatory androstane derivative
US6787532B2 (en)	2000-08-05	2004-09-07	Smithkline Beecham Corporation	Formulation containing anti-inflammatory androstane derivatives
GB0019172D0 (en)	2000-08-05	2000-09-27	Glaxo Group Ltd	Novel compounds
US6750210B2 (en)	2000-08-05	2004-06-15	Smithkline Beecham Corporation	Formulation containing novel anti-inflammatory androstane derivative
CN1294141C (zh)	2000-08-05	2007-01-10	葛兰素集团有限公司	作为抗炎剂的6α，9α－二氟-17α－[(2－呋喃基羧基)氧基]－11β－羟基－16α－甲基－3－氧代-雄甾－1，4-二烯－17－硫代羧酸S－氟甲酯
US6777400B2 (en)	2000-08-05	2004-08-17	Smithkline Beecham Corporation	Anti-inflammatory androstane derivative compositions
US6777399B2 (en)	2000-08-05	2004-08-17	Smithkline Beecham Corporation	Anti-inflammatory androstane derivative compositions
GB0021927D0 (en) *	2000-09-07	2000-10-25	Glaxo Group Ltd	Use of pharmaceutical combination
US7776315B2 (en)	2000-10-31	2010-08-17	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Pharmaceutical compositions based on anticholinergics and additional active ingredients
DE50115277D1 (de) *	2000-10-31	2010-02-04	Boehringer Ingelheim Pharma	Arzneimittelkompositionen aus tiotropiumsalzen und
CN1237970C (zh) *	2000-10-31	2006-01-25	贝林格尔英格海姆法玛两合公司	含提欧川平盐的溶液的可吸入制剂
US20020137764A1 (en)	2000-10-31	2002-09-26	Karin Drechsel	Inhalable formulation of a solution containing a tiotropium salt
UA77656C2 (en)	2001-04-07	2007-01-15	Glaxo Group Ltd	S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent
MXPA03009940A (es)	2001-04-30	2004-01-29	Glaxo Group Ltd	DERIVADOS ANTI-INFLAMATORIOS DE 17. BETA-CARBOTIOATO ESTER DE ANDROSTANO CON UN GRUPO DE ESTER CICLICO EN LA POSICIoN 17.ALFA.
GB2389530B (en)	2002-06-14	2007-01-10	Cipla Ltd	Pharmaceutical compositions
JP4320217B2 (ja) *	2002-07-10	2009-08-26	剤盛堂薬品株式会社	鼻炎用経口製剤
BR0313611A (pt)	2002-08-30	2005-06-21	Altana Pharma Ag	Uso da combinação de ciclesonida e anti-histaminas para o tratamento de rinite alérgica
CN100348166C (zh)	2002-09-20	2007-11-14	Fmc有限公司	含有微晶纤维素的化妆品组合物
MXPA05005044A (es) *	2002-11-12	2005-07-01	Alcon Inc	El uso de un agente antialergico y un esteroide para tratar rinitis alergica.
US20050192261A1 (en) *	2003-09-15	2005-09-01	Jost-Price Edward R.	Methods and reagents for the treatment of immunoinflammatory disorders
WO2005030331A1 (en) *	2003-09-26	2005-04-07	Fairfield Clinical Trials, Llc	Combination antihistamine medication
US20070020299A1 (en) *	2003-12-31	2007-01-25	Pipkin James D	Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
EP1744760B1 (de) *	2004-04-22	2015-01-07	AcuCort AB	Pharmazeutische zusammensetzungen für die akute glucocorticoid-therapie
US20050255154A1 (en)	2004-05-11	2005-11-17	Lena Pereswetoff-Morath	Method and composition for treating rhinitis
US20070020330A1 (en)	2004-11-24	2007-01-25	Medpointe Healthcare Inc.	Compositions comprising azelastine and methods of use thereof
KR20070104884A (ko)	2004-11-24	2007-10-29	메드포인트 헬쓰케어 인크.	아젤라스틴을 포함하는 조성물 및 이의 사용 방법
PL1919450T3 (pl) *	2005-09-01	2014-11-28	Meda Ab	Kompozycja liposomowa zawierająca lek przeciwhistaminowy i kortykosteroid oraz jej zastosowanie do wytwarzania leku do leczenia nieżytu nosa i chorób spokrewnionych
JP2010531898A (ja) *	2007-06-28	2010-09-30	サイデックス・ファーマシューティカルズ・インコーポレイテッド	鼻および眼へのコルチコステロイド水溶液送達
US8569273B2 (en)	2009-03-17	2013-10-29	Aciex Therapeutics, Inc.	Ophthalmic formulations of cetirizine and methods of use
PT2408453T (pt)	2009-03-17	2022-04-05	Nicox Ophthalmics Inc	Formulações oftálmicas de cetirizina e métodos de utilização
US20120323178A1 (en)	2011-01-04	2012-12-20	Mitsubishi Tanabe Pharma Corporation	Bepotastine compositions
FR2970180B1 (fr) *	2011-01-06	2013-08-02	Substipharm Dev	Procede de preparation de suspensions aqueuses pharmaceutiques comprenant un medicament efficace dans le traitement des rhinites
AU2012291841A1 (en)	2011-08-02	2014-02-06	Cipla Limited	Pharmaceutical composition comprising ebastine and fluticasone
CN106074387B (zh) *	2016-08-15	2019-09-13	辽宁大学	具有触变性的曲安奈德鼻喷雾剂及其制备方法
WO2020168289A1 (en) *	2019-02-15	2020-08-20	Ferrer Medical Innovations, LLC	Nasal spray compositions and related treatment methods
EP3941450A4 (de)	2019-03-22	2022-12-21	Dbbh, Llc	Intranasal verabreichte antihistamine und deren verwendung
US20230338279A1 (en) *	2020-04-14	2023-10-26	Glaxosmithkline Consumer Healthcare Holdings (Us) Llc	Nasal spray formulation with moisturizing benefits
US10874650B1 (en) *	2020-04-24	2020-12-29	Ferrer Medical Innovations, LLC	Antiviral and virucidal nasal spray compositions and related treatment methods
AU2022461734A1 (en) *	2022-06-01	2025-01-09	Sato Pharmaceutical Co., Ltd.	Nasal composition

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU6290396A (en) *	1995-06-29	1997-01-30	Mcneil-Ppc, Inc.	The combination of topical nasal mast cell stabilizers and topical nasal steroids
WO1997001337A1 (en) *	1995-06-29	1997-01-16	Mcneil-Ppc, Inc.	The combination of topical nasal antihistamines and topical nasal steroids
EP0780127A1 (de) *	1995-12-19	1997-06-25	The Procter & Gamble Company	Nasenspray enthaltend einen Steroid und einen Antihistamin

1997
- 1997-06-03 EP EP97926878A patent/EP0954318A1/de not_active Withdrawn
- 1997-06-03 BR BR9709650A patent/BR9709650A/pt not_active Application Discontinuation
- 1997-06-03 WO PCT/US1997/009518 patent/WO1997046243A1/en not_active Application Discontinuation
- 1997-06-03 CA CA002256721A patent/CA2256721A1/en not_active Abandoned
- 1997-06-03 AU AU31537/97A patent/AU3153797A/en not_active Abandoned
- 1997-06-03 JP JP10500771A patent/JPH11511758A/ja active Pending

Also Published As

Publication number	Publication date
BR9709650A (pt)	1999-08-10
AU3153797A (en)	1998-01-05
EP0954318A1 (de)	1999-11-10
JPH11511758A (ja)	1999-10-12
WO1997046243A1 (en)	1997-12-11

Publication	Publication Date	Title
CA2256721A1 (en)	1997-12-11	A nasal spray containing an intranasal steroid and an antihistamine
EP0780127A1 (de)	1997-06-25	Nasenspray enthaltend einen Steroid und einen Antihistamin
US8133502B2 (en)	2012-03-13	System for delivering a composition to the nasal membrane and method of using same
DE60034476T2 (de)	2008-01-03	Topische nasenbehandlung mit desloratadin und mometason furoat
KR20190022476A (ko)	2019-03-06	화합물의 국소 도포용 조성물
EP1265615A2 (de)	2002-12-18	Neue kombination nichtsedierender antihistaminika mit substanzen, die die leukotrienwirkung beeinflussen, zur behandlung der rhinitis/konjunktivitis
AU5421198A (en)	1998-06-29	Novel unit dose of budesonide
US9023815B2 (en)	2015-05-05	Method for treating rhinitis and sinusitis by rhamnolipids
US6790847B2 (en)	2004-09-14	Topical application of cetirizine and loratadine
CA2281789A1 (en)	1998-11-05	Topical nasal antiinflammatory compositions
WO2004019955A1 (en)	2004-03-11	The use of the combination of ciclesonide and antihistamines for the treatment of allergic rhinitis
US4885305A (en)	1989-12-05	Nasal compositions
EP0571670B1 (de)	1997-02-05	Pharmazeutische Zusammensetzungen zur Verwendung als Mastzellstabilisator
MXPA98010222A (en)	1999-04-27	Nasal atomizer containing an intranasal steroid and an antihistam
EP1006969A1 (de)	2000-06-14	Intranasale formulierungen zur förderung des schlafs sowie verfahren zu deren verwendung
JP2021504325A (ja)	2021-02-15	鼻副鼻腔炎を治療するためのケルセチンベースの組成物
JP2003055206A (ja)	2003-02-26	鼻腔用医薬組成物
JP2003063957A (ja)	2003-03-05	点鼻剤
EA041137B1 (ru)	2022-09-19	Дозирующее устройство и фармацевтическая композиция для лечения ринита
Trommer et al.	2013	Absorption Enhancers
MXPA99007597A (en)	2000-02-02	Topical nasal antiinflammatory compositions
IT9048064A1 (it)	1991-12-14	Composizioni farmaceutiche a base di calcitonina somministrabili per via nasale in terapia umana

Legal Events

Date	Code	Title	Description
1998-11-30	EEER	Examination request
2002-06-03	FZDE	Dead